Men diagnosed with high-risk localized prostate cancer now have trial-level evidence that adding the drug apalutamide to ...

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...

A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...

PROTEUS results reshape high‑risk localized prostate cancer care, adding apalutamide plus androgen deprivation before surgery as a new option. The phase 3 PROTEUS trial data may add a new ...

Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two full years alongside radiation can meaningfully reduce the chance the ...

A quality improvement study analyzed the value of advanced telehealth delivery methods during prostate cancer management.

Patients who received ADT for 3 months or 9 months had worse overall survival than those treated for 36 months. For men with prostate cancer treated with definitive radiotherapy, the benefit derived ...

Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...